Dr. John Cush RheumNow

4 years ago

A Convergence of Ideas: COVID19 and ACR by Dr. Kathryn Dao (@KDAO2011) #ACR20 https://t.co/0Rxv9GjOkw https://t.co/2uOiOZfSfM

https://bit.ly/2IfFZFL

Meral K. El Ramahi, MD MeralElRamahiMD

4 years ago

Poll results are in! Most would like to wait for a phase III before prescribing MMF with pegloticase in refractory gout. @RheumNow #ACR20 https://t.co/45MpFliDkE

https://twitter.com/meralelramahimd/status/1325219148591456257

Leonard Calabrese LCalabreseDO

4 years ago

Please join me for a special lecture tomorrow NOON as #ACR breaks through the ceiling to discuss THE SCIENCE OF #empathy - so privileged to do this @RheumNow @CCalabreseDO @HealioRheum @HelenRiessMD https://t.co/TDkLK8GaZJ

https://twitter.com/LCalabreseDO/status/1314535200152588288

k dao KDAO2011

4 years ago

#ACRKnowledgeBowl #acr20 @rheumnow This % of bone loss is assc with a T-score -1.5 on a DXA

sheila RHEUMarampa

4 years ago

Learning points from Dr. Janeth Yinh's talk on the utility of #mskus in evaluating painful wrist structures: 👉consider tendon tears in IA 👉consider anatomic variations in pts w/ recalcitrant CTS @RheumNow #ACR20 https://t.co/F2cwxAlfoU

Evolution of GCA Treatments - More to Come

Meral K. El Ramahi, MD, FACP, FACR

4 years ago

The field of Rheumatology is an ever-nascent field with an incredible expansion in our therapeutic armamentarium over the past half century. An example of such advancement is easily appreciated when reflecting on the innovative treatment approach to Giant Cell Arteritis (GCA), the most common form of vasculitis in patients older than 50 years of age.

Mrinalini Dey DrMiniDey

4 years ago

Looking forward to learning lots of #rheumatology "pearls and myths" in this session by Prof. John Stone #ACR20 @RheumNow https://t.co/p6vKd8DZLI

Sole RetamozoSole

4 years ago

Don’t forget to check the eyes. Dr Kolfenbach. Top secret and Pearls #ACR20 @RheumNow It’s also useful for dx #sjogren #sarcoidodis #Ig G4 https://t.co/dxmwuwrPqz

Dr. Antoni Chan synovialjoints

4 years ago

Lots of interesting studies in Spondyloarthritis including AxSpA and PsA at #ACR20 @RheumNow https://t.co/tIyqyMdmTf

https://twitter.com/rheumnow/status/1325475676640645128

Juan Camilo Sarmiento-Monroy jcsam25

4 years ago

@RetamozoSole @RheumNow @Reumaclinic @MAS_Clinic @hospitalclinic #ACR20 Thanks for sharing! but our data show that patients under anti-Cytokine therapy in monotherapy at baseline (specifically anti-IL6 -IL12/23 and -IL17) or under JAKinh were ⬇️LESS likely to be admitted (OR 0.15; 95% CI 0.03-0.66; p=0.012) 📍Limitations: small number of pts https://t.co/zeLzrNLeDQ